Telmicard 80 mg (Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Telmisartan |
| Company | Drug international ltd |
| Also available as |
Title
Telmicard Tablets
Categories
- Hypertension Medication
- Cardiovascular Drug
Description
Telmicard is indicated for the treatment of essential hypertension in adults and reduction of cardiovascular morbidity in adults with atherothrombotic cardiovascular disease, type 2 diabetes mellitus with documented target organ damage, and history of coronary heart disease, stroke, or peripheral arterial disease. It is a non-peptide angiotensin-ll receptor antagonist with dose-related blood pressure response and much greater affinity for the AT1 receptor than for the AT2 receptor. Telmicard tablets should be administered with or without food, and dosage must be individualized. It should be avoided in cases of known hypersensitivity to the product or any of its components.
Color Options
- White
Dimensions
Small tablets
Functions
- Reduces blood pressure
- Blocks vasoconstrictor and aldosterone-secreting effects of angiotensin-ll
Materials
- Active ingredient: Telmisartan
Technical Specifications
- Usual starting dose of 40 mg once a day
- Blood pressure response is dose-related over the range of 20 to 80 mg
Design Elements
- Non-peptide angiotensin-ll receptor antagonist
Usability Features
- Individualized dosage
- Can be administered with other antihypertensive agents
Age Group
- Adults
Treatment Area
- Hypertension
- Cardiovascular System
Indications
- Treatment of essential hypertension in adults
- Reduction of cardiovascular morbidity in adults with atherothrombotic cardiovascular disease or type 2 diabetes mellitus with documented target organ damage
Pharmacology
- Blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin-ll
- Has much greater affinity for the AT1 receptor than for the AT2 receptor
Dosage & Administration
- Usual starting dose of 40 mg once a day
- Blood pressure response is dose-related over the range of 20 to 80 mg
- Can be administered with or without food
- Not recommended in patients ≥75 years old or with hepatic impairment
Pediatric Use
The safety and effectiveness of Telmisartan in pediatric patients have not been established.
Geriatric Use
No overall differences in effectiveness and safety were observed in these patients compared to younger patients.
Hepatic Impairment
Monitor carefully and up titrate slowly in patients with biliary obstructive disorders or hepatic insufficiency
Interactions
- Increased risk of renal impairment and loss of antihypertensive effect when co-administered with NSAIDS
- Co-administration with aliskiren in patients with diabetes should be avoided
Contraindications
Known hypersensitivity to this product or any of its components
Side Effects
- Sinus pain and congestion, back pain, diarrhea (hypertensive patients)
- Intermittent claudication, skin ulcer (patients of cardiovascular risk reduction)
Pregnancy & Lactation
Pregnancy Category C (first trimester) and D (second and third trimester). Potential adverse effects on the nursing infant
Precautions & Warnings
- Avoid fetal or neonatal exposure
- Hypotension
- Avoid concomitant use of an ACE inhibitor and angiotensin receptor blocker
Overdose Effects
- Hypotension
- Dizziness
- Tachycardia
- Bradycardia
- Increase in serum creatinine
- Acute renal failure
Therapeutic Class
Angiotensin-ll receptor blocker
Storage Conditions
- Do not store above 30°C
- Protect from light and high humidity
- Keep out of the reach of children